415 related articles for article (PubMed ID: 21323872)
21. Clinical evaluation of extract of Cajanus cajan (Ciklavit) in sickle cell anaemia.
Akinsulie AO; Temiye EO; Akanmu AS; Lesi FE; Whyte CO
J Trop Pediatr; 2005 Aug; 51(4):200-5. PubMed ID: 15917266
[TBL] [Abstract][Full Text] [Related]
22. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.
Tubman VN; Mejia P; Shmukler BE; Bei AK; Alper SL; Mitchell JR; Brugnara C; Duraisingh MT
Antimicrob Agents Chemother; 2016 Jan; 60(1):613-6. PubMed ID: 26459896
[TBL] [Abstract][Full Text] [Related]
23. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Reid ME; El Beshlawy A; Inati A; Kutlar A; Abboud MR; Haynes J; Ward R; Sharon B; Taher AT; Smith W; Manwani D; Ghalie RG
Am J Hematol; 2014 Jul; 89(7):709-13. PubMed ID: 24677033
[TBL] [Abstract][Full Text] [Related]
24. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
[TBL] [Abstract][Full Text] [Related]
25. Hydroxyurea in the treatment of sickle-cell anemia.
Howard LW; Kennedy LD
Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
[TBL] [Abstract][Full Text] [Related]
26. Antioxidant vitamins C and E supplementation increases markers of haemolysis in sickle cell anaemia patients: a randomized, double-blind, placebo-controlled trial.
Arruda MM; Mecabo G; Rodrigues CA; Matsuda SS; Rabelo IB; Figueiredo MS
Br J Haematol; 2013 Mar; 160(5):688-700. PubMed ID: 23278176
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
28. Types of crises in sickle cell disease patients presenting at the haematology day care unit (HDCU), University College Hospital (UCH), Ibadan.
Olabode JO; Shokunbi WA
West Afr J Med; 2006; 25(4):284-8. PubMed ID: 17402517
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
Wymer JP; Simpson J; Sen D; Bongardt S;
Clin J Pain; 2009 Jun; 25(5):376-85. PubMed ID: 19454870
[TBL] [Abstract][Full Text] [Related]
30. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
31. Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channel-like activity inhibited by senicapoc.
Rivera A; Vandorpe DH; Shmukler BE; Gallagher DR; Fikry CC; Kuypers FA; Brugnara C; Snyder LM; Alper SL
Am J Hematol; 2017 Jun; 92(6):E108-E110. PubMed ID: 28295477
[No Abstract] [Full Text] [Related]
32. Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients.
Manrique RV
J Med; 1987; 18(5-6):277-91. PubMed ID: 3333162
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
[TBL] [Abstract][Full Text] [Related]
34. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea.
Ballas SK; Marcolina MJ; Dover GJ; Barton FB
Br J Haematol; 1999 May; 105(2):491-6. PubMed ID: 10233426
[TBL] [Abstract][Full Text] [Related]
35. Effects of N-acetylcysteine on dense cell formation in sickle cell disease.
Pace BS; Shartava A; Pack-Mabien A; Mulekar M; Ardia A; Goodman SR
Am J Hematol; 2003 May; 73(1):26-32. PubMed ID: 12701116
[TBL] [Abstract][Full Text] [Related]
36. Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients-a randomized placebo-controlled trial.
Diop S; Soudré F; Seck M; Guèye YB; Diéye TN; Fall AO; Sall A; Thiam D; Diakhaté L
Ann Hematol; 2011 Jan; 90(1):23-7. PubMed ID: 20694469
[TBL] [Abstract][Full Text] [Related]
37. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
Al-Jam'a AH; Al-Dabbous IA
Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
[TBL] [Abstract][Full Text] [Related]
38. Senicapoc: a potent candidate for the treatment of a subset of hereditary xerocytosis caused by mutations in the Gardos channel.
Rapetti-Mauss R; Soriani O; Vinti H; Badens C; Guizouarn H
Haematologica; 2016 Nov; 101(11):e431-e435. PubMed ID: 27443288
[No Abstract] [Full Text] [Related]
39. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
[TBL] [Abstract][Full Text] [Related]
40. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
